DermaSensor Announces Four Major New Industry Partnerships to Accelerate Growth in the US
MIAMI, Florida. — September 1, 2026 / businesswire.com/ DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, today announced a major expansion of its U.S. commercial strategy through a series of strategic partnerships to accelerate adoption of its FDA cleared, handheld skin cancer detection device across primary care, enterprise healthcare, and federal healthcare systems.
The Company’s commercial expansion includes 1) an approved supplier relationship with Henry Schein, Inc., the world’s largest provider of healthcare solutions to office-based dental and medical practitioners, 2) a new customer partnership with a major healthcare institution that employs tens of thousands of providers across the U.S., 3) a commercial partnership with MedTech MedCare (MTMC), the largest U.S. medical device contract sales company and 4) a partnership with Medical Place as DermaSensor’s exclusive reseller to the U.S. Department of Veterans Affairs (VA). Together, these partnerships establish a scalable commercial infrastructure that significantly expands access to DermaSensor’s technology to further accelerate the Company’s growth.
“Our mission is to empower clinicians with data-driven, breakthrough technology that improves skin cancer care,” said Cody Simmons, Co-Founder & CEO of DermaSensor. “These partnerships represent an important milestone in our commercialization strategy. They greatly expand our reach across community practices, enterprise healthcare organizations, and federal healthcare systems, positioning us well to impact millions of patients in the years to come, with over 40,000 suspicious lesions already scanned to date.”
DermaSensor is the first and only device cleared by the FDA that provides any kind of risk assessment for the three common skin cancers. The AI-powered, non-invasive technology provides an immediate, objective skin cancer risk result to support physicians’ decision-making for lesion suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma. The FDA pivotal studies demonstrated 96% device sensitivity¹ with over 1,000 patients and that device use reduces missed skin cancer referrals by more than 50%² with over 100 primary care physicians.
New Industry Partnerships
DermaSensor continues to execute against its commercialization strategy through several significant initiatives that expand access to its technology across enterprise healthcare, independent practices, and federal healthcare systems:
Henry Schein Approved Supplier: Launched as an approved supplier with Henry Schein Medical, the medical business of Henry Schein, Inc., a products, services, and technology platforms company serving more than 1 million customers globally. The relationship enables streamlined procurement of DermaSensor and expands access to the device for primary care practices and healthcare systems nationwide.
Major Healthcare Provider Institution Partnership: Completed a nationwide agreement with a major healthcare institution that employs tens of thousands of providers. Any of their divisions can now easily deploy DermaSensor devices, and two divisions are already in the processing of implementing DermaSensor devices at their facilities this year
MedTech MedCare (MTMC) Sales Partnership: MTMC is the largest medical device contract sales company in the US, with >150 sales team members across acute, post-acute, and ambulatory care markets. This partnership has already been implemented successfully in Texas and is now expanding several other states to strengthen provider awareness, expand field coverage, and accelerate commercial adoption of DermaSensor. “Our focus has always been on bringing innovative medical technologies to providers in a way that drives adoption and improves patient care,” said Jack Moran, CEO of MTMC. “DermaSensor represents a meaningful advancement in frontline skin cancer risk detection, and we’re excited to support its commercial expansion through our national sales organization.”
Exclusive U.S. Department of Veterans Affairs (VA) Reseller Partnership: Appointed Medical Place, a federal healthcare distributor with more than 43 years of experience serving VA medical centers and federal healthcare facilities, as DermaSensor’s exclusive reseller to the U.S. Department of Veterans Affairs. The agreement establishes a dedicated commercial pathway into one of the nation’s largest integrated healthcare systems and expands access to DermaSensor’s technology for veterans nationwide. “We believe DermaSensor has the potential to become an important technology within the VA healthcare system,” said Dr. Alfred Seawright, CEO, Medical Place. “This exclusive agreement reflects our confidence in the Company’s technology and our commitment to making skin cancer detection more accessible to our veterans, who have a three-hold higher prevalence of skin cancer.” ³
Together, these four major commercial partnerships significantly expand DermaSensor’s reach across the U.S. healthcare market and strengthen the infrastructure needed to support broad adoption. With expanded access secured across enterprise healthcare organizations, independent practices, national distribution channels, and federal healthcare systems, DermaSensor is well positioned to accelerate commercialization and advance its mission to save lives by improving early skin cancer detection.
About DermaSensor
DermaSensor Inc. is a Miami-based medical device company that enables healthcare professionals to effectively check for skin cancer by leveraging cutting-edge technologies. The DermaSensor™ device is a non-invasive, handheld system that uses artificial intelligence and spectroscopy to immediately test skin lesions for cancer. By enabling quick and effective skin cancer checks, DermaSensor aims to improve skin cancer detection and save lives. DermaSensor is FDA cleared (Class II De Novo), CE Marked (Class IIb), and is currently available for sale in the U.S.
For more information, visit www.dermasensor.com.
References:
1. Merry SP et al. Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer. Journal of Primary Care & Community Health. 2025;16. doi:10.1177/21501319251344423
2. Ferris LK et al. DERM-SUCCESS FDA Pivotal Study: A Multi-Reader Multi-Case Evaluation of Primary Care Physicians’ Skin Cancer Detection Using AI-Enabled Elastic Scattering Spectroscopy. J Prim Care Community Health. 2025;16:21501319251342106. doi:10.1177/21501319251342106
3. Rezaei SJ et al. Skin Cancer and Other Dermatologic Conditions Among US Veterans. JAMA Dermatol. 2024 Oct 1;160(10):1107-1111. doi: 10.1001/jamadermatol.2024.3043.
